Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial.

被引：0
|
作者：
Soto, C. [1 ]
Torrecillas, L. [1 ]
Reyes, S. [1 ]
Ramirez, M. [1 ]
Perez, L. [1 ]
Cervantes, G. [1 ]
Gonzalez, F. [1 ]
Tellez, E. [1 ]
Cortes, P. [1 ]
Benitez, H. [1 ]
机构：
[1] ISSSTE, IMSS, Mexico City, DF, Mexico
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：20S / 20S
页数：1
相关论文
共 50 条
  • [11] Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
    Chan, Stephen
    Romieu, Gilles
    Huober, Jens
    Delozier, Thierry
    Tubiana-Hulin, Michele
    Schneeweiss, Andreas
    Lluch, Ana
    Llombart, Antonio
    du Bois, Andreas
    Kreienberg, Rolf
    Mayordomo, Jose Ignacio
    Anton, Antonio
    Harrison, Mark
    Jones, Alison
    Carrasco, Eva
    Vaury, A. Thareau
    Frimodt-Moller, Bente
    Fumoleau, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1753 - 1760
  • [12] A phase III trial of Gemcitabine plus Docetaxel (GD) versus Capecitabine plus Docetaxel (CD) for patients (pt) with anthracycline-pretreated metastatic breast cancer
    Chan, S.
    Sharma, R.
    Romieu, G.
    Huober, T.
    Delozier, T.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, A.
    Fumoleau, P.
    EJC SUPPLEMENTS, 2007, 5 (03): : 15 - 16
  • [13] Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC).
    Beslija, S.
    Obralic, N.
    Basic, H.
    Tatarevic, A.
    Naila, M.
    Banjin, M.
    Cardzic, A.
    Sosevic, A.
    Pasic, A.
    Ceric, T.
    Salkic, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 20S - 20S
  • [14] Gemcitabine-oxaliplatin combination (SEGEMOX) in anthracycline (A) and taxanes (T) pretreated metastatic breast cancer (MBC): Results from the GERCOR-SEGEMOX phase II trial
    Gligorov, J.
    Cals, L.
    Tournigand, C.
    Merad, Z.
    Dutel, J.
    Selle, F.
    Zeghib, N.
    Chibaudel, B.
    Cvitkovic, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [15] A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer
    Bayo, Juan
    Lomas, Maria
    Salvador, Javier
    Moreno, Alberto
    Ruiz, Manuel
    Rodriguez, Alberto
    Fuentes, Jose
    Fernandez-Freire, Ana
    Bernabe, Reyes
    Fernandez, Andrea
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (12): : 817 - 825
  • [16] A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer
    Juan Bayo
    María Lomas
    Javier Salvador
    Alberto Moreno
    Manuel Ruiz
    Alberto Rodríguez
    José Fuentes
    Ana Fernández-Freire
    Reyes Bernabé
    Andrea Fernández
    Clinical and Translational Oncology, 2008, 10
  • [17] Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Sparano, Joseph A.
    Vrdoljak, Eduard
    Rixe, Oliver
    Xu, Binghe
    Manikhas, Alexey
    Medina, Carlos
    Ventilari Da Costa, Susanne Crocamo
    Ro, Jungsil
    Rubio, Gonzalo
    Rondinon, Monica
    Perez Manga, Gumersindo
    Peck, Ronald
    Poulart, Valerie
    Conte, Pierfranco
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3256 - 3263
  • [18] A phase I/II study of oral capecitabine (X) and vinorelbine (V) as second- or -third line chemotherapy in anthracycline/taxane pretreated patients (pts) with metastatic breast cancer (MBC).
    Kellokumpu-Lehtinen, P
    Sjoström, J
    Sunela, K
    Lehtinen, I
    Joensuu, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S70 - S70
  • [19] Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC).
    Lee, KS
    Lee, ES
    Kwon, YM
    Nam, BH
    Kwon, HS
    Chung, KW
    Kang, HS
    Kim, EA
    Kim, SW
    Ro, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S224 - S224
  • [20] Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
    Yamamoto, Daigo
    Sato, Nobuaki
    Rai, Yoshiaki
    Yamamoto, Yutaka
    Saito, Mitsue
    Iwata, Hiroji
    Masuda, Norikazu
    Oura, Shoji
    Watanabe, Junichiro
    Hattori, Satoshi
    Matsuura, Yoshimasa
    Kuroi, Katsumasa
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) : 473 - 482
12345